# Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention

> **NCT04425993** · NA · UNKNOWN · sponsor: **Air Force Military Medical University, China** · enrollment: 2700 (actual)

## Conditions studied

- Post-ERCP Acute Pancreatitis

## Interventions

- **DRUG:** Isosorbide Dinitrate 5 MG
- **DRUG:** Indomethacin 100 MG
- **DRUG:** Sublingual Placebo
- **DRUG:** Rectal placebo

## Key facts

- **NCT ID:** NCT04425993
- **Lead sponsor:** Air Force Military Medical University, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-01
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 2700 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425993, "Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04425993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*